On November 11, Finnegan client International CSRC Investment Holdings Co. announced that Sanofi’s U.S. subsidiary Genzyme Corp agreed to pay $180 million to resolve a licensing dispute and to end the arbitrations they initiated over royalties for patents directed to treatments for Pompe disease, a rare neuromuscular disorder. The arbitrations were initiated by Genzyme through the American Arbitration Association (AAA) after Genzyme claimed that their royalty obligations expired earlier than the initial licensing agreement terms.
Read “Sanofi Unit To Pay $180M in Disease Treatment Patent Fight”
